Dernières nouvelles pour Sutro Biopharma (NASDAQ:STRO) Stock

SUTRO BIOPHARMA INC

Sutro Biopharma

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Sutro Biopharma Inc

Strong

STRONG GLOBAL ENTMT INC CL A COM VOTING SHS

Stroeer SE & Co KGaA

STROEER SE CO UNSP/ADR by Stroeer SE and Co

Stronghold Digital Mining Inc

Stronghold Token

STROUD RESOURCES LTD by Stroud Resources Ltd.

Stroud Resources Ltd

WIIM

FOSL

Fossil Group shares are trading higher after the company reported a year-over-year increase in Q1 adjusted EPS results.

CABA

Cabaletta Bio shares are trading higher after the company announced its eyeing a 2027 BLA submission for rese-cel in myositis after aliging with the FDA on registrations cohorts.

Needham analyst Tom Nikic downgrades Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) from Buy to Hold and announces $24 price target.

News

Downgrades

Price Target

Analyst Ratings

Needham Downgrades Foot Locker to Hold, Announces $24 Price Target

IXHL

Incannex Healthcare shares are trading highera fter the company reported a year-over-year increase in Q3 EPS results.

UOKA

MDJM shares are trading lower after the company announced a 25-for-1 share consolidation.

NAOV

Nanovibronix shares are trading lower after the company announced a $10 million public offering.

VIRT

Virtu Financial shares are trading lower after B of A Securities downgraded the stock from Buy to Neutral.

Dillard's shares are trading higher after the company reported better-than-expected Q1 EPS results.

Tower Semiconductor Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) on Wednesday reported <a href="https://www.benzinga.com/news/earnings/25/05/45408724/tower-semiconductor-stock-dips-despite-q1-revenue-growth-as-margins-squeeze">mixed results for the first quarter</a>.
The company's RF Infrastructure business continued to deliver strong growth driven by dataceter and AI expansions, according to Benchmark.
The Tower Semiconductor Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e2ae9e3430dee0001c80e0c/cody-acree">Analyst Cody Acree</a> maintained a Buy rating and price target of $60.
The Tower Semiconductor Thesis: The RF Infrastructure business grew from accounting for 14% of the company's revenues last year to 22% in the first quarter, Acree said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Tower Semiconductor's first-quarter revenues grew to $358.2 million, up 9% year-on-year and 6% sequentially, he added.
The revenues came in-line with expectations due to the high degree of visibility afforded by "virtually 100% of any given quarter booked in the prior periods," the analyst stated. The company's earnings came in at 45 cents per share, beating consensus by 7 cents per share, he said.
"With a high degree of management's enthusiasm regarding its expected continued business momentum, we believe Tower is well positioned to capitalize on what we see as the early days of the next industry upcycle," Acree further wrote.
TSEM Price Action: Shares of Tower Semiconductor had declined by 0.58% to $41.90 at the time of publication on Thursday.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45262278/under-armour-faces-tough-road-ahead-says-analyst"> Tower Semiconductor Adapts To Nvidia&#8217;s Architectural Shift, Analyst Sees Growth In AI Optical Networks</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings

Reiteration

TSEM

Tower Semiconductor Is Well Positioned In The 'Early Days Of The Next Industry Upcycle,' Says Bullish Analyst

Nextracker shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY26 sales guidance above estimates. Additionally, the company announced it acquired Bentek Corp for $78 million and several firms raised their respective price targets on the stock.

Stride (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>) has outperformed the market over the past 5 years by 31.23% on an annualized basis producing an average annual return of 46.31%. Currently, Stride has a market capitalization of $6.69 billion. 
Buying $1000 In LRN: If an investor had bought $1000 of LRN stock 5 years ago, it would be worth $6,596.02 today based on a price of $153.93 for LRN at the time of writing.
<h3>Stride's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747327536_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Stride 5 Years Ago Would Be Worth This Much Today

RBC Capital analyst Matthew Swanson maintains IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with a Outperform and raises the price target from $276 to $285.

RBC Capital Maintains Outperform on IBM, Raises Price Target to $285

Deere shares are trading higher after the company reported Q2 financial results and beat its EPS and revenue estimates.

Live On CNBC, Jenny Harrington Announces Bought Ethan Allen Interiors

Live On CNBC, Jim Labenthal Announces Bought More Lockheed Martin

Chubb shares are trading higher after the company increased its quarterly dividend from $0.91 to $0.97 per share and announced authorization for a new $5 billion stock repurchase program.

RBC Capital analyst Kenneth Lee maintains FS KKR Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSK#NYSE">FSK</a>) with a Sector Perform and lowers the price target from $22 to $21.

RBC Capital Maintains Sector Perform on FS KKR Capital, Lowers Price Target to $21

TOST

Live On CNBC, Josh Brown Hosts Segment Titled "Josh's Best Stock Spotlight: Toast"

Abbott Laboratories shares are trading higher after the company announced its REFLECT real-world studies showed positive results in the reduction of risk for heart complications for people with diabetes.

RBC Capital analyst Matthew Hedberg maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Outperform and raises the price target from $55 to $60.

RBC Capital Maintains Outperform on Dynatrace, Raises Price Target to $60

Press Releases

Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Health Care

Management

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

Small Cap

Opinion

New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty

Sutro Biopharma to Participate in Upcoming Investor Conferences

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

Comments

Sutro Biopharma

Actualités

Dernières nouvelles pour Sutro Biopharma (NASDAQ:STRO) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL